GammaDeltaTME
Financiado
Cellular and molecular regulators of the pleiotropic activities of gamma delta T...
Cellular and molecular regulators of the pleiotropic activities of gamma delta T cells in the tumor microenvironment
Immune cells constitute a major component of the tumor microenvironment (TME) that influence several aspects of cancer progression and outcome. The host laboratory has identified two distinct γδ T-cell subsets with opposing roles...
Immune cells constitute a major component of the tumor microenvironment (TME) that influence several aspects of cancer progression and outcome. The host laboratory has identified two distinct γδ T-cell subsets with opposing roles in tumor progression: whereas interferon-γ (IFN-γ)-producing γδ T-cells stimulate anti-tumor responses, IL-17A-secreting γδ T-cells promote angiogenesis and tumor growth. However, the cellular and molecular factors controlling the critical balance between these antagonistic subsets remain unknown.
The present proposal builds on subsequent relevant findings of the host laboratory, namely that neutrophils suppress IL-17A+ γδ T-cell proliferation, revealing an unanticipated neutrophil/γδ T-cell crosstalk in TME, and that on another side the metabolic resources may also play a critical role in γδ T-cell subsets.
Based on these foundations, within the present proposal we will:
a) identify TME cellular partners that determine the balance between IFN-γ+ and IL-17A+ γδ T-cells in several experimental models of cancer.
b) study the metabolic pathways employed by γδ T-cell subsets and the impact of manipulating those pathways on their balance within the TME
c) analyze the impact of immune crosstalk and metabolic resources on γδ T-cell subsets both at transcriptomic and epigenetic levels.
Overall, this project will provide conceptual advances that will foster innovative strategies to promote anti-tumor γδ cell functions at the expense of their pro-tumoral activities.
ver más
Duración del proyecto: 33 meses
Fecha Inicio: 2020-03-24
Fecha Fin: 2023-01-14
Fecha Fin: 2023-01-14
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2023-01-14
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
WF-02-2019:
Widening Fellowships
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
160K€
Líder del proyecto
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
426.42K€ |
Participante